Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.53 |
| ▸ | ACACA | Q13085 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | CPT2 | P23786 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.33 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.32 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186814 | 1.00 | ACACB (0.53) | ACACBACACAFFAR1CPT2TDP1 | |
| SCHEMBL10257266 | 1.00 | ACACB (0.53) | ACACBACACAFFAR1CPT2TDP1 | |
| SCHEMBL186512 | 1.00 | ACACB (0.53) | ACACBACACAFFAR1CPT2TDP1 | |
| SCHEMBL186531 | 0.98 | ACACB (0.50) | ACACBACACAFFAR1CPT2TDP1 | |
| SCHEMBL13106363 | 0.94 | ACACB (0.48) | ACACBACACAFFAR1CPT2TDP1 | |
| SCHEMBL207907 | 0.94 | ACACB (0.48) | ACACBACACAFFAR1CPT2TDP1 | |
| SCHEMBL13106111 | 0.93 | ACACB (0.43) | ACACBACACAFFAR1CPT2TDP1 | |
| SCHEMBL186477 | 0.93 | ACACB (0.43) | ACACBACACAFFAR1CPT2TDP1 | |
| SCHEMBL12092749 | 0.92 | ACACB (0.47) | ACACBACACAFFAR1CPT2TDP1 | |
| SCHEMBL12092754 | 0.92 | ACACB (0.47) | ACACBACACAFFAR1CPT2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210800-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230210800-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20210395175-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-10941095-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20190263742-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-10118881-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| US-20170349516-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170349516-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170349516-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| EP-2404890-B1 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20070155704-A1 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155704-A1 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | DASSEUX JEAN-LOUIS H | 2007-06-28 | — | — | US | disclosed |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | DASSEUX JEAN-LOUIS H | 2007-06-28 | — | — | US | disclosed |
| EP-1701931-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics, Inc. (US) | 2006-09-20 | — | — | EP | disclosed |
| EP-1597223-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005068412-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| US-20050043278-A1 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | GLAS AMERICAS LLC | 2005-02-24 | — | — | US | disclosed |
| US-20040198814-A1 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2004-10-07 | — | — | US | disclosed |
| WO-2004067489-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263742-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | NR1H3, CYP27A1, NR1H2 | ACACB 543/4885ACACA 495/4885FFAR1 205/4885 |
| US-20170349516-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | NR1H3, CYP27A1, NR1H2 | ACACB 543/4885ACACA 495/4885FFAR1 205/4885 |
| US-10941095-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | NR1H3, CYP27A1, NR1H2 | ACACB 543/4885ACACA 495/4885FFAR1 205/4885 |
| US-20210395175-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | NR1H3, CYP27A1, NR1H2 | ACACB 543/4885ACACA 495/4885FFAR1 205/4885 |
| US-20070155704-A1 | Ketone compounds and compositions for cholesterol management and related uses | PC, HMGCR, GPR119 | ACACB 91/4885ACACA 38/4885FFAR1 126/4885 |
| US-20040198814-A1 | Ketone compounds and compositions for cholesterol management and related uses | PC, HMGCR, GPR119 | ACACB 91/4885ACACA 38/4885FFAR1 126/4885 |
| US-20230210800-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | CYP27A1, NR1H3, PNLIP | ACACB 645/4885ACACA 460/4885FFAR1 163/4885 |
| US-10118881-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | NR1H3, CYP27A1, NR1H2 | ACACB 543/4885ACACA 495/4885FFAR1 205/4885 |
| US-20050043278-A1 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | PNLIP, NR1H3, CYP27A1 | ACACB 220/4885ACACA 202/4885FFAR1 166/4885 |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PC, HMGCR, GPR119 | ACACB 91/4885ACACA 38/4885FFAR1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.